RETATRUTIDE

Retatrutide is an investigational GLP-1, GIP and glucagon receptor agonist compound described in the scientific literature as a triple agonist. This listing is supplied at a stated 60mg presentation for qualified healthcare professionals only, where local regulations permit. Composition, presentation, expiry, storage and permitted use are stated on the product labelling and in the accompanying batch documentation.

Retatrutide is characterised in published research as a single molecule with agonist activity at three receptors: GLP-1, GIP and glucagon. These receptors are studied for their roles in incretin signalling and energy metabolism. This description reflects the general scientific understanding of the molecule class and is not a claim about the performance of this specific presentation.

Retatrutide is the subject of ongoing and emerging research. Peer-reviewed literature and trial records can be searched at pubmed.ncbi.nlm.nih.gov and clinicaltrials.gov. Published findings relate to specific study populations, formulations and conditions, and are not claims that this product reproduces those results. Regeniq does not summarise trial endpoints as product claims.

Any consideration of this material sits entirely with the qualified clinician, within their own scope of practice and the applicable regulatory framework in their jurisdiction. Regeniq does not recommend indications, protocols, dosing schedules, reconstitution steps or administration technique, and does not present this product as a substitute for an approved medicine.

Retatrutide is investigational. Its regulatory status and any permitted use vary significantly by jurisdiction, and it is not approved for general retail sale or self-administration where that is prohibited. It is the responsibility of the clinician to verify the current rules that apply in their market before ordering or using this material. Safety, efficacy and long-term outcome data remain incomplete. No outcome is implied or guaranteed.

Selected professional reading:

• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389:514-526. doi:10.1056/NEJMoa2301972.

This citation describes a specific investigational clinical-trial material, protocol and population. It is not evidence that this product is equivalent to the studied material or will reproduce the published findings. Retatrutide remains investigational; clinicians must verify current trial, regulatory and supply status independently.

Store exactly as stated on the supplied product labelling. Regeniq does not publish storage conditions for this item on this page; follow the label and the accompanying batch documentation supplied with your order. Do not use beyond the expiry date shown on the labelling. If the labelling is missing or unclear, contact us before use.

This material is intended for qualified healthcare professionals only and is not intended for self-administration. Information on this page is general, is not medical advice, and does not replace consultation with a qualified healthcare professional. Product labelling and local regulations govern how this product may be supplied, stored and used in your market. Review the accompanying batch documentation before use.

Orders are dispatched only where supply is permitted in the destination market. Delivery timelines and return conditions are set out in our shipping and refund policies. Contact us with your order number and we will confirm the next step.